Company intelligence / Profile preview
Vor Bio
Cambridge, Massachusetts, United Statesvorbio.com ↗
- Ownership
- Public · VOR
- Employees
- ~159
- Development stage
- Phase 1
01
Overview
Vor Bio’s lead program involves gene-editing donor hematopoietic stem cells to remove CD33 expression (“trem-cel”), allowing patients to receive anti-CD33 therapies such as Mylotarg without damaging healthy blood cells. Early clinical results are promising for enabling targeted therapy post-transplant while protecting normal hematopoiesis. Multiple clinical trials are ongoing for AML and MDS patients.
- Therapeutic areas
- OncologyHematology
- Modalities
- Hematopoietic stem cell (HSC) transplants (gene-edited)Chimeric Antigen Receptor T cells (CAR-T)Antibody Drug Conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed; collaborations with academic founders.Scientific & Clinical Advisors include leading experts in oncology and cell/gene therapy fields.
04
Financials
- Market cap
- $1B
- Total revenue
- $0
- Enterprise value
- $532.4M
Beyond the preview
Go deeper on Vor Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vor Bio.